Rhythm Pharmaceuticals, Inc.
RYTM
$90.51
$3.133.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 189.76M | 174.33M | 156.29M | 136.86M | 130.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 189.76M | 174.33M | 156.29M | 136.86M | 130.13M |
| Cost of Revenue | 19.49M | 18.48M | 16.81M | 14.21M | 13.37M |
| Gross Profit | 170.27M | 155.86M | 139.48M | 122.65M | 116.76M |
| SG&A Expenses | 194.94M | 175.59M | 158.54M | 149.01M | 144.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 381.77M | 268.14M | 241.33M | 217.09M | 210.83M |
| Operating Income | -192.02M | -93.81M | -85.04M | -80.22M | -80.71M |
| Income Before Tax | -196.04M | -191.89M | -183.08M | -168.57M | -260.22M |
| Income Tax Expenses | 497.00K | 438.00K | -17.00K | 125.00K | 345.00K |
| Earnings from Continuing Operations | -196.54 | -192.33 | -183.06 | -168.69 | -260.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -196.54M | -192.33M | -183.06M | -168.69M | -260.57M |
| EBIT | -192.02M | -93.81M | -85.04M | -80.22M | -80.71M |
| EBITDA | -190.68M | -92.36M | -83.51M | -78.68M | -79.14M |
| EPS Basic | -3.11 | -3.10 | -3.02 | -2.82 | -4.36 |
| Normalized Basic EPS | -1.89 | -0.94 | -0.90 | -0.86 | -0.87 |
| EPS Diluted | -3.11 | -3.10 | -3.02 | -2.82 | -4.36 |
| Normalized Diluted EPS | -1.89 | -0.94 | -0.90 | -0.86 | -0.87 |
| Average Basic Shares Outstanding | 259.88M | 254.60M | 249.56M | 246.89M | 243.97M |
| Average Diluted Shares Outstanding | 259.88M | 254.60M | 249.56M | 246.89M | 243.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |